Many drugs work by binding to a specific target in the body and blocking or chan
- Source
- x.com
- Date
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
Context
A protein binder is a protein built to attach tightly to one chosen target in the body, which is how many drugs block or change what that target does. Designing one is an early step in drug development, and Anthropic describes it as weeks or months of expert work per target, spent sifting many candidates to find the few that work. In an August 18 post, Anthropic says it tested whether Claude could design new binders from scratch, which the field calls de novo design. Working from a protein-design prompt written by a human expert, Claude "autonomously designed protein binders against 14 out of 15 targets," according to the company (Anthropic on X).
The post adds that two outside companies, Adaptyv Bio and Twist Bioscience, independently built and tested the proteins Claude designed. It does not report what those laboratory tests found, such as how many individual designs actually bound their targets, and the video attached to the post could not be reviewed. The post on its own therefore shows the scope of the experiment, not how often the designs worked. Anthropic published the methods and full results in a follow-up research post, which is where those numbers should be checked.
Checking sign-in…
Loading comments…






